Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 901–1,000 of 1,045
Camidge, D. R., Morgensztern, D., Heist, R. S., Barve, M. A., Vokes, E. E., Goldman, J. W., Hong, D. S., Bauer, T. M., Strickler, J. H., Angevin, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0765 · Cited by 85
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
Andrini, E., Marchese, P. V., de Biase, D., Mosconi, C., SIEPE, G., Panzuto, F., Ardizzoni, A., Campana, D., & Lamberti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051461 · Cited by 89
“Molecular patterns Oncogene-addicted (~30%) Six molecular subtypes in LUAD [23], four in LSCC [24] Non-oncogene addicted (~70%) SCLC-A (ASCL1) SCLC-N (NEUROD1) SCLC-P (POU2F3) SCLC-Y/I (YAP1/Inflamed) [25] Type I (TP53, KEAP1, STK11) Type II (TP53 and RB1 co-inactivation)”
BackgroundInfluentialMyc Expression Drives Aberrant Lipid Metabolism in Lung Cancer
Hall, Z., Ament, Z., Wilson, C. H., Burkhart, D. L., Ashmore, T., Koulman, A., Littlewood, T. D., Evan, G. I., & Griffin, J. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3403 · Cited by 92
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 82
ADAM17: An Emerging Therapeutic Target for Lung Cancer
Saad, M. I., Rose‐John, S., & Jenkins, B. J. (2019) · Cancers · doi:10.3390/cancers11091218 · Cited by 89
“Following this discovery, oncogenic KRAS mutations were identified as a common feature of LAC (accounting for 33% of all LAC patients) and other human cancers [3,9].”
BackgroundMiddleton, G., Crack, L. R., Popat, S., Swanton, C., Hollingsworth, S. J., Buller, R., Walker, I., Carr, T. H., Wherton, D., & Billingham, L. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv394 · Cited by 82
Thangavelu, P. U., Krenács, T., Dray, E. V., & Duijf, P. H. G. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0290-6 · Cited by 85
Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma
Toyokawa, G., Kozuma, Y., Matsubara, T., Haratake, N., Takamori, S., Akamine, T., Takada, K., Katsura, M., Shimokawa, M., Shoji, F., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.108 · Cited by 79
CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
Liu, B., Saber, A., & Haisma, H. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.011 · Cited by 93
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Terry, S., Abdou, A., Engelsen, A. S. T., Buart, S., Dessen, P., Corgnac, S., Collares, D., Meurice, G., Gausdal, G., Baud, V., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0903 · Cited by 84
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers
Tanaka, H., & Watanabe, T. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.019 · Cited by 84
Ebisudani, T., Hamamoto, J., Togasaki, K., Mitsuishi, A., Sugihara, K., Shinozaki, T., Fukushima, T., Kawasaki, K., Seino, T., Oda, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112212 · Cited by 85
Jeon, M. J., Chun, S., Kim, D., Kwon, H., Jang, E. K., Kim, T. Y., Kim, W. B., Shong, Y. K., Jang, S. J., Song, D. E., et al. (2016) · Thyroid · doi:10.1089/thy.2015.0506 · Cited by 79
Sun, Q., Li, S., Wang, Y., Peng, H., Zhang, X., Zheng, Y., Li, C., Li, L., Chen, R., Chen, X., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-017-0034-y · Cited by 87
Leshchiner, I., Livitz, D., Gainor, J. F., Rosebrock, D., Spiro, O., Martinez, A., Mroz, E., Lin, J. J., Stewart, C., Kim, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/508127 · Cited by 79
Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
Lee, B., Lee, T., Lee, S.-H., Choi, Y.-L., & Han, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8074 · Cited by 78
Self-citationScagliotti, G. V., Moro‐Sibilot, D., Kollmeier, J., Favaretto, A. G., Cho, E. K., Grosch, H., Kimmich, M., Girard, N., Tsai, C., Hsia, T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.003 · Cited by 81
Li, Y., Li, X., Li, H., Zhao, Y., Liu, Z., Sun, K., Zhu, X., Qi, Q., An, B., Shen, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01409-2019 · Cited by 78
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Van Ness, B., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 78
Parker, A. L., Bowman, E. D., Zingone, A., Ryan, B. M., Cooper, W. A., Kohonen‐Corish, M. R. J., Harris, C. C., & Cox, T. R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01127-6 · Cited by 81
Mok, T. S. K., Lopes, G., Cho, B. C., Kowalski, D. M., Kasahara, K., Wu, Y.-L. L. C., de Castro, G., Turna, H. Z., Cristescu, R., Aurora-Garg, D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.011 · Cited by 88
A large‐scale analysis of alternative splicing reveals a key role of QKI in lung cancer
de Miguel, F. J., Pajares, M. J., Martínez‐Terroba, E., Ajona, D., Morales, X., Sharma, R. D., Pardo, F. J., Rouzaut, A., Rubio, Á., Montuenga, L. M., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.08.001 · Cited by 77
Okimoto, R. A., Lin, L., Olivas, V., Chan, E., Markegard, E., Rymar, A., Neel, D., Chen, X., Hemmati, G., Bollag, G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610456113 · Cited by 78
Zhou, X., Updegraff, B. L., Guo, Y., Peyton, M., Girard, L., Larsen, J. E., Xie, X.-J., Zhou, Y., Hwang, T. H., Xie, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1267-t · Cited by 78
Terry, S., Buart, S., Tan, T. Z., Gros, G., Noman, M. Z., Lorens, J. B., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1271858 · Cited by 78
Benamar, M., Guessous, F., Du, K., Corbett, P., Obeid, J., Gioeli, D., Slingluff, C. L., & Abbas, T. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.06.023 · Cited by 77
“Publicly available TCGA data at cBioPortal (Cerami et al., 2012; Gao et al., 2013) was used to plot Kaplan-Meier plots on tumors divided into two groups based on level of CDT2 expressed as a Z-score (Collisson et al., 2014; Taylor et al., 2010; Weinstein et al., 2014).”
MethodRecurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
Graham, N. A., Minasyan, A., Lomova, A., Cass, A. A., Balanis, N. G., Friedman, M., Chan, S. T., Zhao, S. R., Delgado, A., Go, J. L., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167159 · Cited by 100
Martínez‐Martí, A., Felip, E., Matito, J., Mereu, E., Navarro, A., Cedrés, S., Pardo, N., de Castro, A. M. M., Remón, J., Miquel, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx396 · Cited by 77
Ma, P., Fu, Y., Cai, M., Yan, Y., Jing, Y., Zhang, S., Chen, M., Wu, J., Shen, Y., Zhu, L. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00963-0 · Cited by 78
Brinkman, A. B., Nik‐Zainal, S., Simmer, F., Rodríguez-González, F. G., Smid, M., Alexandrov, L. B., Butler, A. P., Martin, S., Davies, H. R., Głodzik, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09828-0 · Cited by 87
Jurišić, V., Vuković, V., Obradović, J., Gulyaeva, L. F., Кушлинский, Н. Е., & Djordjević, N. (2020) · Journal of Oncology · doi:10.1155/2020/1973241 · Cited by 91
Zhao, J., Guo, C., Ma, Z., Liu, H., Yang, C., & Li, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.014 · Cited by 82
Chang, A., Liu, L., Ashby, J. M., Wu, D., Chen, Y., O’Neill, S. S., HUANG, S. H., Wang, J., Wang, G., Cheng, D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0688 · Cited by 77
Soltis, A. R., Bateman, N. W., Liu, J., Nguyen, T. M., Franks, T. J., Zhang, X., Dalgard, C. L., Viollet, C., Somiari, S., Yan, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100819 · Cited by 93
Benchmarking integration of single-cell differential expression
Hai, N. C. T., Baik, B., Yoon, S., Park, T., & Nam, D. (2023) · Nature Communications · doi:10.1038/s41467-023-37126-3 · Cited by 87
Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma
Fan, C., Chen, L., Huang, Q., Shen, T., Welsh, E. A., Teer, J. K., Cai, J., Cress, W. D., & Wu, J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.378 · Cited by 78
Noh, K., Lee, M., Lee, S. E., Song, J., Shin, H., Kim, Y. J., Oh, D. Y., Jung, K., Sung, M., Kim, M., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4950 · Cited by 82
Comparison of algorithms for the detection of cancer drivers at subgene resolution
Porta-Pardo, E., Kamburov, A., Tamborero, D., Pons, T., Grases, D., Valencia, A., Lopez-Bigas, N., Getz, G., & Godzik, A. (2017) · Nature Methods · doi:10.1038/nmeth.4364 · Cited by 76
Characteristics of genomic alterations of lung adenocarcinoma in young never‐smokers
Luo, W., Tian, P., Wang, Y., Xu, H., Chen, L., Tang, C., Shu, Y., Zhang, S., Wang, Z., Zhang, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31542 · Cited by 76
Afshar, A. R., Pekmezci, M., Bloomer, M. M., Cadenas, N., Stevers, M., Banerjee, A., Roy, R., Olshen, A. B., Ziffle, J. V., Onodera, C. S., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.12.005 · Cited by 76
Drugging All RAS Isoforms With One Pocket
Kessler, D., Bergner, A., Böttcher, J., Fischer, G., Döbel, S., Hinkel, M., Müllauer, B., Weiss-Puxbaum, A., & McConnell, D. B. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0221 · Cited by 73
Xue, Y., Morris, J. L., Yang, K., Fu, Z., Zhu, X., Johnson, F. D., Meehan, B., Witkowski, L., Yasmeen, A., Golenár, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25260-9 · Cited by 91
Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq
Li, Q., Wang, R., Yang, Z., Li, W., Yang, J., Wang, Z., Bai, H., Cui, Y., Tian, Y., Wu, Z., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01089-9 · Cited by 90
ROS1 Fusions in Cancer: A Review
Uguen, A., & Braekeleer, M. D. (2016) · Future Oncology · doi:10.2217/fon-2016-0050 · Cited by 83
Kazandjian, D. G., Blumenthal, G. M., Luo, L., He, K., Fran, I., Lemery, S. J., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0101 · Cited by 79
Lazarus, K., Hadi, F., Zambon, E., Bach, K., Santolla, M., Watson, J., Correia, L., Das, M., Ugur, R., Pensa, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05790-5 · Cited by 65
Edlund, K., Madjar, K., Mattsson, J. S. M., Djureinovic, D., Lindskog, C., Brunnström, H., Koyi, H., Brandén, E., Jirström, K., Pontén, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.022 · Cited by 84
Optogenetic engineering to probe the molecular choreography of STIM1-mediated cell signaling
Ma, G., He, L., Liu, S., Xie, J., Huang, Z., Ji, J., Lee, Y., Wang, R., Luo, H., Han, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14841-9 · Cited by 81
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1
Romero, R., Sánchez-Rivera, F. J., Westcott, P. M. K., Mercer, K. L., Bhutkar, A., Muir, A., González Robles, T. J., Lamboy Rodríguez, S., Liao, L. Z., Ng, S. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0071-1 · Cited by 75
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
Yan, N., Guo, S., Zhang, H., Zhang, Z., Shen, S., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863043 · Cited by 87
Serra, V., Wang, A. T., Castroviejo‐Bermejo, M., Polanska, U. M., Palafox, M., Herencia-Ropero, A., Jones, G. N., Lai, Z., Armenia, J., Michopoulos, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0568 · Cited by 77
A Clinician’s Guide to Bioinformatics for Next-Generation Sequencing
Larson, N. B., Oberg, A. L., Adjei, A. A., & Wang, L. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.006 · Cited by 100
Wang, Y., Liu, B., Min, Q., Yang, X., Yan, S., Ma, Y., Li, S., Fan, J., Wang, Y., Dong, B., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00591-7 · Cited by 94
Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.
Khoo, C., Rogers, T.-M., FELLOWES, A. P., Bell, A. H., & Fox, S. B. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.10 · Cited by 85
Biology of MET: a double life between normal tissue repair and tumor progression.
Petrini, I. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.03.58 · Cited by 75
Tumor molecular profiling of NSCLC patients using next generation sequencing
Τσούλος, Ν., Papadopoulou, E., Metaxa-Mariatou, V., Tsaousis, G., Efstathiadou, C., Tounta, G., Scapeti, A., Bourkoula, E., Zarogoulidis, P., Pentheroudakis, G. E., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6051 · Cited by 81
Lee, W.-C., Diao, L., Wang, J., Zhang, J., Roarty, E. B., Varghese, S., Chow, C.-W. B., Fujimoto, J., Behrens, C., Cascone, T., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0029-3 · Cited by 80
Rühm, W., Eidemüller, M., & Kaiser, J. C. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1310405 · Cited by 77
“2012) or EGFR-related and KRAS-related pathways in adenocarcinoma of the lung (Collisson et al. 2014).”
BackgroundInfluentialXiao, J., Lu, X., Chen, X., Zou, Y., Liu, A., Li, W., He, B., He, S., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17606 · Cited by 75
Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma
Nagahashi, M., Sato, S., Yuza, K., Shimada, Y., Ichikawa, H., Watanabe, S., Takada, K., Okamoto, T., Okuda, S., Lyle, S. R., et al. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.07.007 · Cited by 78
Targeting RET-rearranged non-small-cell lung cancer: future prospects
Bronte, G., Ulivi, P., Verlicchi, A., Cravero, P., Delmonte, A., & Crinò, L. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s192830 · Cited by 87
JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
Mohrherr, J., Haber, M., Breitenecker, K., Aigner, P., Moritsch, S., Voronin, V., Eferl, R., Moriggl, R., Stoiber, D., Győrffy, B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32624 · Cited by 80
Hai, J., Zhang, H., Zhou, J. R., Wu, Z., Chen, T., Papadopoulos, E., Dowling, C. M., Pyon, V., Pan, Y., Liu, J. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1627 · Cited by 77
Canale, M., Petracci, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., Luigi, N. D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041047 · Cited by 81
KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub
Scalera, S., Mazzotta, M., Cortile, C., Krasniqi, E., Maria, R. D., Cappuzzo, F., Ciliberto, G., & Maugeri‐Saccà, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.011 · Cited by 83
Dysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 80
The miR-17∼92 microRNA Cluster Is a Global Regulator of Tumor Metabolism
Izreig, S., Samborska, B., Johnson, R. M., Sergushichev, A., Ma, E. H., Lussier, C. R., Loginicheva, E., Donayo, A. O., Poffenberger, M. C., Sagan, S. M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.036 · Cited by 88
Hou, S., Zhou, S., Qin, Z., Liu, Y., Han, X., Yao, S., & Ji, H. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.009 · Cited by 81
Metabolic rewiring in mutant Kras lung cancer
Kerr, E. M., & Martins, C. P. (2017) · FEBS Journal · doi:10.1111/febs.14125 · Cited by 83
Vanderdys, V., Allak, A., Guessous, F., Benamar, M., Read, P. W., Jameson, M. J., & Abbas, T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0083 · Cited by 81
“The Cancer Genome Atlas TCGA data, publicly available at cBioPortal (32, 33), was used to plot Kaplan-Meier plots on tumors divided into two groups based on CDT2 expression as a Z-score (34-36).”
MethodWang, L., Zhao, H., Xu, Y., Li, J., Deng, C., Deng, Y., Bai, J., Li, X., Xiao, Y., & Zhang, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31865 · Cited by 75
Negrao, M. V., Raymond, V. M., Lanman, R. B., Robichaux, J. P., He, J., Nilsson, M. B., Ng, P. K., Amador, B. E., Roarty, E. B., Nagy, R. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.021 · Cited by 79
Tyler, M. P. H., & Tirosh, I. (2021) · Nature Communications · doi:10.1038/s41467-021-22800-1 · Cited by 80
Yazaki, K., Matsuno, Y., Yoshida, K., Sherpa, M., Nakajima, M., Matsuyama, M., Kiwamoto, T., Morishima, Y., Ishii, Y., & Hizawa, N. (2021) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2021.151181 · Cited by 73
Gao, Z., Hong, B., Li, Y., Zhang, X., Wu, J., Wang, C., Zhang, X., Gong, T., Zheng, Y., Meng, D., et al. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102652 · Cited by 77
Node-aligned Graph Convolutional Network for Whole-slide Image Representation and Classification
Guan, Y., Zhang, J., Tian, K., Yang, S., Dong, P., Xiang, J., Yang, W., Huang, J., Zhang, Y., & Han, X. (2022) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr52688.2022.01825 · Cited by 100
“NSCLC is one of the most common primary lung cancer types, which contains two cancer subtypes: Lung Adenocarcinoma (LUAD) [6] and Lung Squamous Cell Carcinoma (LUSC) [28].”
BackgroundTwo-pass alignment improves novel splice junction quantification
Veeneman, B. A., Shukla, S., Dhanasekaran, S. M., Chinnaiyan, A. M., & Nesvizhskii, A. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv642 · Cited by 72
LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity
Zeltz, C., Pasko, E., Cox, T. R., Navab, R., & Tsao, M. (2019) · Cancers · doi:10.3390/cancers11050705 · Cited by 75
PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer
Reda, M. M., Ngamcherdtrakul, W., Gu, S., Bejan, D. S., Siriwon, N., Gray, J. W., & Yantasee, W. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.014 · Cited by 80
TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis
Yan, D., Wang, J., Sun, H., Zamani, A., Zhang, H., Chen, W., Tang, A., Ruan, Q., Yang, X., Chen, Y. H., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182005 · Cited by 78
ULK1-ATG13 and their mitotic phospho-regulation by CDK1 connect autophagy to cell cycle
Li, Z., Tian, X., Ji, X., Wang, J., Chen, H., Wang, D., & Zhang, X. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000288 · Cited by 59
Koppula, P., Olszewski, K. L., Zhang, Y., Kondiparthi, L., Liu, X., Lei, G., Das, M., Fang, B., Poyurovsky, M. V., & Gan, B. (2021) · iScience · doi:10.1016/j.isci.2021.102649 · Cited by 82
“For glucose- or cystine-deprivation experiments, cells were cultured in glucose and/or cystine-free DMEM with dialyzed FBS as previously described (Chauhan et al., 2019; Lee et al., 2020; Lin et al., 2014b).”
MethodReese, M., & Dhayat, S. A. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01149-4 · Cited by 88
Kawasaki, K., Rekhtman, N., Quintanal-Villalonga, À., & Rudin, C. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00696-0 · Cited by 77
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges
Yu, Y., Yang, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102520 · Cited by 84
In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation
Cortez, M. A., Valdecanas, D., Niknam, S., Peltier, H. J., Diao, L., Giri, U., Komaki, R., Calin, G. A., Gomez, D. R., Chang, J. Y., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.47 · Cited by 72
Udager, A. M., McHugh, J. B., Betz, B. L., Montone, K. T., LiVolsi, V. A., Seethala, R. R., Yakirevich, E., Iwenofu, O. H., Perez‐Ordoñez, B., DuRoss, K. E., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4750 · Cited by 74
Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Huang, Q., Schneeberger, V. E., Luetteke, N., Jin, C., Afzal, R., Budzevich, M. M., Makanji, R. J., Martinez, G. V., Shen, T., Zhao, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0258 · Cited by 77
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
Öner, D., Ghosh, M., Bové, H., Moisse, M., Boeckx, B., Duca, R. C., Poels, K. L. C., Luyts, K., Putzeys, E., LANDUYT, K. L. V., et al. (2018) · Particle and Fibre Toxicology · doi:10.1186/s12989-018-0244-6 · Cited by 75
Ooki, A., Dinalankara, W., Marchionni, L., Tsay, J.-C. J., Goparaju, C. M. V., Maleki, Z., Rom, W. N., Pass, H. I., & Hoque, M. O. (2018) · Oncogene · doi:10.1038/s41388-018-0373-2 · Cited by 72
Schrock, A. B., Welsh, A. W., Chung, J., Pavlick, D. C., Bernicker, E., Creelan, B., Forcier, B., Ross, J. S., Stephens, P. J., Ali, S. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.008 · Cited by 75
Molecular Pathology of Lung Cancer
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 99
Chen, M., Liu, X., Du, J., Wang, X., & Xia, L. (2016) · Oncotarget · doi:10.18632/oncotarget.13346 · Cited by 76
“As the most common subtypes of NSCLC, LUAD and LUSC differ from each other in many aspects [9, 10].”
BackgroundmiR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop
Shi, L., Wang, Y., Lü, Z., Zhang, H., Zhuang, N., Wang, B., Song, Z., Chen, G., Huang, C., Xu, D., et al. (2016) · Oncogene · doi:10.1038/onc.2016.332 · Cited by 73
Massarelli, E., Lam, V. K. L., Parra, E. R., Rodriguez‐Canales, J., Behrens, C., Diao, L., Wang, J., Blando, J. M., Byers, L. A., Yanamandra, N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0827-2 · Cited by 78
Tan, X., Lu, T., Li, L., Xu, J., Xie, S., Ji, L., Fu, J., Liu, Q., Shen, S., Liu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24898-9 · Cited by 72
Scalera, S., Mazzotta, M., Corleone, G., Sperati, F., Terrenato, I., Krasniqi, E., Pizzuti, L., Barba, M., Vici, P., Gallo, E., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.010 · Cited by 80
Lung cancer risk in never-smokers: An overview of environmental and genetic factors
Cheng, E. S., Weber, M. F., Steinberg, J., & Yu, X. Q. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.05.02 · Cited by 97
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
Izumi, H., Matsumoto, S., Liu, J., Tanaka, K., Mori, S., Hayashi, K., Kumagai, S., Shibata, Y., Hayashida, T., Watanabe, K., et al. (2021) · Nature · doi:10.1038/s41586-021-04135-5 · Cited by 76
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.